Teva's picked an address in Parsippany, New Jersey, and the dirt's about to fly

Teva
Teva's 12-year New Jersey lease will reportedly set the company back $9 million. (Teva)

Teva now knows where it's headed in New Jersey, but it’s still got plenty of work to do before it can move into its new U.S. headquarters.

The Israeli pharma, which said earlier this month that it would move its U.S. home from Pennsylvania to the Garden State, has inked a 12-year lease for a 360,000-square-foot office building in Parsippany, NJ.com reports.

The office space won’t come cheap. The generics giant will reportedly shell out about $9 million in rent as part of a deal that “took a lot of give and take on both sides,” according to Harvey Rosenblatt, founder of the real estate developer that owns and manages the property.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

The fact that Teva was already a tenant in the building, which is part of the MCC Blue office complex on Parsippany’s Interspace Parkway, helped seal the deal.

RELATED: Teva, lured by $40M tax break, packs its bags for New Jersey HQ move

On top of the hefty rent sum, Teva will be undertaking a massive construction project. “It is an astronomical build-out process,” Rosenblatt told the publication.

Thanks to an incentive package from New Jersey, though, Teva has the funds to get it done. To lure the pharma from its longtime Pennsylvania headquarters in North Wales, the state offered up $40 million in tax credits.

RELATED: What’s a move to New Jersey worth? For Teva’s U.S. headquarters, $40M in tax breaks

Teva’s move comes as the company works to consolidate sites and increase efficiency as part of its $3 billion cost-cutting drive. The plan, which will claim 14,000 jobs when all is said and done, had already affected Teva’s Pennsylvania workers before the company locked in on a relocation.

But Teva may have been weighing a switch long before it actually pulled the trigger. The company had been in touch with state officials over the last few years, and it had “various interactions” with the New Jersey Economic Development Authority from 2009 on, a public affairs director at the authority told NJ.com. The state also approved a tax credit package for Teva in early 2012, but Teva later withdrew its application.

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.